AND EXCHANGE COMMISSION
to Section 13 or 15(d) of
Securities Exchange Act of 1934
of Report (Date of Earliest Event Reported): February 22, 2012
name of registrant as specified in its charter)
or other jurisdiction
Park, POB 455
of principal executive offices)
telephone number, including area code +972-4-988-9488
name or former address, if changed since last report.)
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
||Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)|
||Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)|
||Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))|
||Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))|
7.01. Regulation FD Disclosure
February 23, 2012, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that Yossi Maimon,
the Company’s Vice President and Chief Financial Officer, will present at the Citi 2012 Global Health Care Conference on
Monday, February 27, 2012 at 11:00 AM EST. The conference will be held at The Waldorf-Astoria Hotel in New York City on February
27-29, 2012. The press release also announced that Mr. Maimon will be participating in the Credit Suisse Global Healthcare One-on-One
Conference on Wednesday, February 29, 2012. The conference will be held at Credit Suisse’s office in London, England on
February 29, 2012 to March 2, 2012.
copy of the press release is furnished as Exhibit 99.1.
information contained in Item 7.01 of this report and in Exhibit 99.1 shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
8.01. Other Events
February 22, 2012, the Company issued a press release announcing that it has completed its previously announced underwritten public
offering and that the underwriters of the offering exercised, in full, their over-allotment option to purchase an additional 675,000
shares of the Company's common stock in the offering. A copy of the press release is filed as Exhibit 99.2.
9.01. Financial Statements and Exhibits
release, dated February 23, 2012.
release, dated February 22, 2012.
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
February 23, 2012